Table 1.
Characteristics of clinical trials
| Identifier | Status | Year | Study Type | Estimate Enrollment | Intervention | Study Groups/Cohorts | Conditions | Primary Outcome |
|---|---|---|---|---|---|---|---|---|
| NCT03446495 | Unknown | 2018 | Observational | 60 | Trabectedin + PLD | Trabectedin + PLD | Recurrent Partial-platinum Sensitive Ovarian Cancer | PFS |
| NCT03690739 | Recruiting | 2018 | Interventional (Clinical Trial) | 330 | Drug: Carboplatin | Arm A: Active Comparator: platinum-based chemotherapy | Recurrent Ovarian Carcinoma | Symptom Benefit Rate, PFS, OS |
| Randomized | Drug: Gemcitabine | Arm B: PLD + Trabectedin | ||||||
| Drug: Bevacizumab | ||||||||
| Drug: PLD | ||||||||
| Drug: Paclitaxel | ||||||||
| Drug: Trabectedin | ||||||||
| Drug: Cisplatin | ||||||||
| NCT02825420 | Completed | 2016 | Observational | 224 | Trabectedin + PLD | Trabectedin + PLD | Relapsed Ovarian Cancer | PFS |
| NCT02394015 | Completed | 2015 | Observational | 90 | Trabectedin + PLD | Trabectedin + PLD | Recurrent Partial-platinum Sensitive Ovarian Cancer | PFS+OS |
| NCT02163720 | Completed | 2014 | Observational | 101 | Yondelis®-Caelyx® | Yondelis®-Caelyx®-relapse | Recurrent Partial-platinum Sensitive Ovarian Cancer | PFS+OS |
| NCT01846611/ET743-OVC-3006 | Completed | 2013 | Interventional (Clinical Trial) | 576 | Drug: Trabectedin | Arm A: Trabectedin + DOXIL | Ovarian Neoplasms | PFS+OS |
| Randomized | Drug: DOXIL | Arm B: DOXIL | Peritoneal Neoplasms | |||||
| Drug: Dexamethasone | Fallopian Tube Neoplasms | |||||||
| NCT01869400 | Completed | 2013 | Observational | 83 | Yondelis-Pegylated liposomal Doxorubicin | Yondelis-Pegylated liposomal Doxorubicin | Platinum-sensitive ovarian cancer relapse | Safety and tolerability |
| NCT01379989 | Active, not recruiting | 2011 | Interventional (Clinical Trial) | 588 | Drug: Carboplatin | Arm A: Carboplatin + PLD | Recurrent Partial-platinum Sensitive Ovarian Cancer | PFS+OS |
| Randomized | Drug: PLD | Arm B: Trabectedin + PLD | ||||||
| Drug: Trabectedin | ||||||||
| EUCTR2010-022949-17-AT | Unknown | 2010 | Interventional (Clinical Trial) | 600 | Trabectedin | Arm A: Trabectedin + PLD | Recurrent Partial-platinum Sensitive Ovarian Cancer | PFS+OS |
| Randomized | PLD | Arm B: Carboplatin + PLD | ||||||
| Carboplatin | ||||||||
| NCT00113607/OVA-301 | Completed | 2005 | Interventional (Clinical Trial) | 672 | Drug: Trabectedin | Arm A: DOXIL + trabectedin | Advanced Relapsed Ovarian Cancer | PFS+OS |
| Randomized | Drug: DOXIL | Arm B: DOXIL | ||||||
| Drug: Dexamethasone |